# US 2003/0228283 A1 · Preventing secondary lymphedema with VEGF-D DNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228283 A1
- Document ID: US20030228283A1
- Status: Published application
- Kind: A1
- Application number: 10/424,992
- Filed: 2003-04-29
- Published: 2003-12-11
- Earliest claimed: 2002-05-03
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Lucie Margarete Heinzerling; Megan Elizabeth Baldwin; Steven Alan Stacker; Maro Gregory Achen
- Web page: https://patentgrep.com/patent/US20030228283A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61P 7/10: Antioedematous agents; Diuretics
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of preventing secondary lymphedema with DNA encoding VEGF-D and/or VEGF-D protein, and biologically active fragments and analogs thereof, as well as pharmaceutical compositions for treating secondary lymphedema, are presented.

## Claims

### Claim 1

A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding vascular endothelial growth factor-D (VEGF-D).

### Claim 2 (depends on 1)

A method of claim 1, wherein said patient is human

### Claim 3 (depends on 2)

A method of claim 2, wherein said DNA is circular.

### Claim 4 (depends on 3)

A method of claim 3, wherein said DNA is a plasmid.

### Claim 5

A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding VEGF-D,
wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.

### Claim 6 (depends on 5)

A method of claim 5, wherein said edema follows at least one of surgery and radiotherapy for a neoplastic disease.

### Claim 7 (depends on 6)

A method of claim 6, wherein said neoplastic disease is breast cancer.

### Claim 8 (depends on 6)

A method of claim 6, wherein said neoplastic disease is at least one tumor type.

### Claim 9

A method of inhibiting secondary lymphedema, comprising:
administering to a patient at risk for secondary lymphedema a therapeutically inhibitory amount of DNA encoding VEGF-D.

### Claim 10

A method for expressing VEGF-D in a target cell, comprising
selecting a plasmid capable of expressing DNA encoding VEGF-D, wherein said plasmid has at least one insertion site for insertion of said DNA encoding VEGF-D operably linked to a promoter capable of expression in said target cell;
inserting said DNA encoding VEGF-D into said insertion site, and introducing said plasmid into said target cell wherein said DNA encoding VEGF-D is expressed at detectable levels.

### Claim 11

A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of at least one plasmid encoding VEGF-DΔNΔC.

### Claim 12

A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of vascular endothelial growth factor-D (VEGF-D) protein.

### Claim 13 (depends on 12)

A method of claim 12, wherein said patient is human

### Claim 14

A method of treating secondary lymphedema, comprising:
administering to a patient with secondary lymphedema a therapeutically effective amount of VEGF-D protein, wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.

### Claim 15 (depends on 14)

A method of claim 14, wherein said edema follows surgery or radiotherapy for a neoplastic disease.

### Claim 16 (depends on 15)

A method of claim 15 wherein said neoplastic disease is breast cancer.

### Claim 17 (depends on 15)

A method of claim 15, wherein said neoplastic disease is at least one tumor type.

### Claim 18

A method of inhibiting secondary lymphedema, comprising:
administering to a patient at risk for secondary lymphedema a therapeutically preventative amount of VEGF-D protein.

### Claim 19 (depends on 1)

A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one DNA virus.

### Claim 20 (depends on 1)

A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one of an adenovirus, a herpesvirus, a parvovirus, and an avipox virus.

### Claim 21 (depends on 1)

A method of claim 1, wherein said DNA encoding VEGF-D is administered to said patient by at least one liposome.

### Claim 22 (depends on 1)

A method of claim 1, wherein said lymphedema is idiopathic.

### Claim 23 (depends on 12)

A method of claim 12, wherein said lymphedema is idiopathic.
